PL1680112T3 - N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę - Google Patents

N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę

Info

Publication number: PL1680112T3
Authority: PL; Poland
Prior art keywords: treatment; insulin resistance; deoxynojirimycin; adamantane; pentyl
Prior art date: 2003-10-29

Application number

PL04793684T

Other languages

English (en)

Inventor

Johannes Maria Franciscus Gerardus Aerts

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-29

Filing date

2004-10-29

Publication date

2011-05-31

2004-10-29 Application filed by Genzyme Corp filed Critical Genzyme Corp

2011-05-31 Publication of PL1680112T3 publication Critical patent/PL1680112T3/pl

Links

206010022489 Insulin Resistance Diseases 0.000 title abstract 2
LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 title 1
208000031888 Mycoses Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010033307 Overweight Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000000069 hyperpigmentation Diseases 0.000 abstract 1
230000003810 hyperpigmentation Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL04793684T 2003-10-29 2004-10-29 N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę PL1680112T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP03078396		2003-10-29
EP04076936		2004-07-06
PCT/NL2004/000760 WO2005039578A2 (en)	2003-10-29	2004-10-29	Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP04793684A EP1680112B1 (en)	2003-10-29	2004-10-29	N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin or a pharmaceutically salt thereof for use in the treatment of insulin resistance

Publications (1)

Publication Number	Publication Date
PL1680112T3 true PL1680112T3 (pl)	2011-05-31

Family

ID=34524734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04793684T PL1680112T3 (pl)	2003-10-29	2004-10-29	N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę

Country Status (11)

Country	Link
US (1)	US7662838B2 (pl)
EP (1)	EP1680112B1 (pl)
JP (1)	JP2007509925A (pl)
AT (1)	ATE491451T1 (pl)
AU (1)	AU2004283631A1 (pl)
CA (1)	CA2544086A1 (pl)
DE (1)	DE602004030604D1 (pl)
IL (1)	IL175259A0 (pl)
PL (1)	PL1680112T3 (pl)
PT (1)	PT1680112E (pl)
WO (1)	WO2005039578A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1528056A1 (en) *	2003-10-29	2005-05-04	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005092334A2 (en) *	2004-03-25	2005-10-06	David Priestman	Use of n-substituted imino sugars for appetite suppression
BRPI0517701A8 (pt)	2004-11-10	2018-01-23	Genzyme Corp	métodos de tratamento de diabetes mellitus
FR2887549B1 (fr) *	2005-06-23	2009-07-10	Centre Nat Rech Scient	Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
ES2546181T3 (es)	2006-05-09	2015-09-21	Genzyme Corporation	Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
GB0614098D0 (en) *	2006-07-15	2006-08-23	Mnl Pharma Ltd	Immune response variegation with imino sugars
JP2008104399A (ja) *	2006-10-25	2008-05-08	Spirulina Biological Lab Ltd	糖尿病予防食品
EP2594565B1 (en)	2007-05-31	2018-10-24	Genzyme Corporation	2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR101640263B1 (ko)	2007-10-05	2016-07-15	젠자임 코포레이션	세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
JP2011529500A (ja)	2008-07-28	2011-12-08	ジェンザイムコーポレーション	虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CN102271678B (zh)	2008-10-03	2017-06-30	简詹姆公司	2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
US20100248365A1 (en) *	2009-03-27	2010-09-30	Zacharon Pharmaceuticals, Inc.	Ganglioside biosynthesis modulators
WO2013007447A2 (en) *	2011-07-13	2013-01-17	Unilever Plc	Edible composition
WO2014143999A1 (en) *	2013-03-15	2014-09-18	Unither Virology, Llc	Antibacterial compounds
WO2022227287A1 (zh) *	2021-04-25	2022-11-03	中南大学	Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2504000B2 (ja)	1986-09-02	1996-06-05	日本新薬株式会社	グルコシルモラノリン誘導体
US6177447B1 (en)	1996-07-15	2001-01-23	Universiteit Van Amsterdam	Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
BR9902585A (pt) *	1999-02-11	2000-09-26	Claudio Cerqueira Lopes	Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en)	2001-01-12	2001-02-21	Oxford Glycosciences Uk Ltd	Compounds
US6235737B1 (en)	2000-01-25	2001-05-22	Peter Styczynski	Reduction of hair growth
US20040204379A1 (en)	2000-06-19	2004-10-14	Cheng Seng H.	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CA2461818A1 (en) *	2001-10-15	2003-04-24	Genentech, Inc.	Treatment and diagnosis of insulin resistant states
EP1528056A1 (en)	2003-10-29	2005-05-04	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005063706A1 (en)	2003-12-23	2005-07-14	Macrozyme Dnm B.V.	Synthesis of nojirimycins
EP3782655A1 (en)	2005-05-17	2021-02-24	Amicus Therapeutics, Inc.	A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

2004
- 2004-10-29 PL PL04793684T patent/PL1680112T3/pl unknown
- 2004-10-29 WO PCT/NL2004/000760 patent/WO2005039578A2/en not_active Ceased
- 2004-10-29 US US10/595,584 patent/US7662838B2/en not_active Expired - Lifetime
- 2004-10-29 AT AT04793684T patent/ATE491451T1/de not_active IP Right Cessation
- 2004-10-29 CA CA002544086A patent/CA2544086A1/en not_active Abandoned
- 2004-10-29 PT PT04793684T patent/PT1680112E/pt unknown
- 2004-10-29 JP JP2006537908A patent/JP2007509925A/ja active Pending
- 2004-10-29 AU AU2004283631A patent/AU2004283631A1/en not_active Abandoned
- 2004-10-29 EP EP04793684A patent/EP1680112B1/en not_active Expired - Lifetime
- 2004-10-29 DE DE602004030604T patent/DE602004030604D1/de not_active Expired - Lifetime
2006
- 2006-04-27 IL IL175259A patent/IL175259A0/en unknown

Also Published As

Publication number	Publication date
IL175259A0 (en)	2006-09-05
WO2005039578A3 (en)	2005-09-29
CA2544086A1 (en)	2005-05-06
JP2007509925A (ja)	2007-04-19
PT1680112E (pt)	2011-03-24
AU2004283631A1 (en)	2005-05-06
WO2005039578A2 (en)	2005-05-06
EP1680112B1 (en)	2010-12-15
EP1680112A2 (en)	2006-07-19
DE602004030604D1 (de)	2011-01-27
US20070135487A1 (en)	2007-06-14
US7662838B2 (en)	2010-02-16
ATE491451T1 (de)	2011-01-15

Publication	Publication Date	Title
TW200635582A (en)	2006-10-16	Medicaments for the treatment or prevention of fibrotic diseases
IL175259A0 (en)	2006-09-05	Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
FI3457135T3 (fi)	2025-03-08	Fabryn taudin hoitovaihtoehtoja
WO2004030611A3 (en)	2004-06-17	Non-nucleoside reverse transcriptase inhibitors
TWI255817B (en)	2006-06-01	Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
TW200505881A (en)	2005-02-16	Tri(cyclo) substituted amide compounds
IL171683A (en)	2014-07-31	Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
CY1112184T1 (el)	2015-12-09	Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
EP2371853A3 (en)	2012-10-03	Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
UA92000C2 (en)	2010-09-27	1-benzylindole-2-carboxamide derivatives
SG150531A1 (en)	2009-03-30	Use of meloxicam for the treatment of respiratory diseases in pigs
GEP20074047B (en)	2007-02-26	Pramipexole once-daily dosage form
MX2011013902A (es)	2012-02-23	Tratamiento de esclerosis multiple con laquinimod.
IL162765A (en)	2012-04-30	Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
ATE371665T1 (de)	2007-09-15	Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ZA200303037B (en)	2003-11-12	Herbal pharmaceutical composition for treatment of HIV/Aids patients.
RU2004135563A (ru)	2005-06-10	Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2006017188A3 (en)	2006-06-29	Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP2009500045A5 (pl)	2009-07-23
WO2007030944A3 (en)	2007-05-03	Methods of cardioprotection using dichloroacetate in combination with an inotrope
RU2007119067A (ru)	2008-11-27	Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
TW200637544A (en)	2006-11-01	Medicaments for the treatment or prevention of fibrotic diseases
TW200635595A (en)	2006-10-16	Medicaments for the treatment of prevention of fibrotic diseases
WO2005082413A3 (en)	2006-08-24	Ciclesonide and glycopyrronium combination
RU2004105675A (ru)	2005-08-10	Способ комплексного лечения язв роговицы